Basic Biobehavioral

1 Background There are more than 18 million cancer survivors living in the US [1], and this population is expected to exceed 26 million by 2040 [2]. Due to advances in cancer treatment and improved screening practices, cancer survivors are now living longer than ever before, though with increased longevity comes a greater potential for treatment-related adverse effects that may arise months or years after completion of treatment [1].

1. Introduction Cancer and cancer therapies may contribute to the development of early onset frailty, a geriatric syndrome that is indicative of multi-system decline and often precipitates mortality (1–4). The prevalence of frailty has been reported to range from 8% in adult survivors of childhood cancer to 59 percent in older adult cancer survivors using phenotypic and deficit accumulation frailty measures (5).

Dilorom Sass1*, Brennan Parmelee Streck2, Vivian A. De Alvarenga Guedes3, Diane Cooper4, Jennifer L. Guida2 and Terri S.